Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LGMN | Q99538 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ME3 | Q16798 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297594 | 0.89 | USP30 (0.43) | MAPTUSP30CHRM4LMNAGAA | |
| SCHEMBL19297501 | 0.88 | CHRM4 (0.42) | USP30CHRM4EPHX2ME3 | |
| SCHEMBL19297502 | 0.85 | ME3 (0.46) | USP30LMNAGAAEPHX2ME3 | |
| SCHEMBL19297588 | 0.85 | USP30 (0.51) | USP30CNR1CNR2DRD2 | |
| SCHEMBL16277720 | 0.83 | MAPT (0.61) | MAPTALDH1A1TSHRLGMNMEN1 | |
| SCHEMBL23551417 | 0.81 | MAPT (0.42) | MAPTLMNAKDM4EGAAALDH1A1 | |
| SCHEMBL16669381 | 0.79 | NPY5R (0.50) | MAPTCNR1CNR2CHRM4LMNA | |
| SCHEMBL23551462 | 0.77 | MAPT (0.58) | MAPTLMNAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL23538213 | 0.76 | DEGS1 (0.40) | MAPTUSP30LMNAKDM4EALDH1A1 | |
| SCHEMBL14328872 | 0.76 | NPY5R (0.41) | MAPTUSP30CHRM4DRD2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-10478425-B2 | 5-phenylazaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2019-11-19 | — | — | US | disclosed |
| WO-2017146186-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | 塩野義製薬株式会社 | 2017-08-31 | — | — | WO | disclosed |
| EP-3063148-A1 | AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB2, PRKAB1 | MAPT 4427/4885USP30 4024/4885CNR1 1734/4885 |
| US-10478425-B2 | 5-phenylazaindole derivative having AMPK-activating activity | PRKAG2, PRKAG1, PRKAB2 | MAPT 2620/4885USP30 3007/4885CNR1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.